i-mab to Rebrand as Novabridge, Eyes Hong Kong IPO
I-Mab is pivoting to a new operating model and identity, unveiling plans to rebrand as NovaBridge Biosciences, pursue a...
eClinical Tech News
Iovance Biotherapeutics Reports Inducement Grants for New Hires
Iovance Biotherapeutics has granted inducement stock options covering 62,790 shares to nine new non-executive employees, effective October 16, 2025....
Praxis Sees Positive Phase 3 Results for Essential Tremor
Praxis Precision Medicines reported positive topline results from two Phase 3 studies in its Essential3 program for ulixacaltamide in...
ANI Pharma to Present New Day Trial Data at AAO 2025
ANI Pharmaceuticals will deliver a late-breaking oral presentation of the NEW DAY clinical trial for ILUVIEN (fluocinolone acetonide 0.19...
Rakovina Unveils New CNS-Penetrating ATR Inhibitor Data
Rakovina Therapeutics will present new preclinical data on a series of AI-designed ATR inhibitors with central nervous system penetrance...
Minovia Drug MNV-201 Receives FDA Orphan Drug Designation
Minovia Therapeutics has secured FDA Orphan Drug Designation for MNV-201 in myelodysplastic syndromes, adding to the asset’s existing Fast...
Tafenoquine Shows Promise in First Babesiosis Patient Study
60 Degrees Pharmaceuticals reported the first negative post-treatment result in its expanded access study of tafenoquine for relapsing babesiosis...
Regeneron Spotlights Oncology Advances for Tough Cancers
Regeneron will present seven oncology abstracts at ESMO 2025, led by new Phase 3 C-POST safety and pharmacokinetic data...
Bexorg’s Revolutionary AI Platform for CNS gets $42.5M
Bexorg has closed a $23 million Series A led by Engine Ventures, bringing total funding to $42.5 million to...
argenx to Highlight Immunology Data at 2025 AANEM & MGFA
Argenx is using the AANEM Annual Meeting and MGFA Scientific Session to widen the runway for its neuromuscular franchise....